Eurocept Pharmaceuticals

What Eurocept Pharmaceuticals does

Eurocept Pharmaceuticals is a privately held specialty pharmaceutical company headquartered in Ankeveen, the Netherlands, founded in 2001 and operating with a headcount of 51–100 employees (per firmographic inputs). According to the company's stated self-description, Eurocept develops, produces, registers, and markets medicinal products intended for healthcare providers and patients. The vertically integrated scope — spanning development, manufacturing, regulatory registration, and commercialization — places the firm in the mid-market European specialty pharma segment, where it appears to operate as a focused niche player rather than a broad primary-care manufacturer.

Business model mechanics, product portfolio composition, therapeutic areas, pricing, customer mix, and go-to-market channels are not disclosed in the available source material. The company's own website (euroceptpharma.com) returned only a loading/verification screen rather than substantive content, and no third-party sources surfaced management, financials, partnerships, certifications, or pipeline details. Consequently, the precise revenue model — whether driven by originator brands, generics, specialty licensing-in arrangements, or contract manufacturing — cannot be confirmed from evidence on hand.

For an investment audience, the available inputs establish Eurocept as an established (24-year-old), operating, mid-sized, privately held Dutch specialty pharma with internal regulatory and manufacturing capabilities, but the absence of disclosed financials, customer logos, pipeline assets, or strategic actions means most analytical dimensions cannot be evidenced beyond baseline firmographic facts. Deeper diligence would require direct management outreach, Dutch trade register (KvK) filings, and IQVIA or comparable prescription/sales data to substantiate revenue, growth, and competitive positioning.

Name

Eurocept Pharmaceuticals

Legal name

Not available - website content not accessible

Website

https://euroceptpharma.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

51–100 employees

Short description

Eurocept Pharmaceuticals is a privately held Dutch specialty pharma company, founded in 2001 and based in Ankeveen, that develops, produces, registers, and markets medicinal products for healthcare providers and patients.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Pharmaceutical products
• Medicinal products
• Pharmaceutical distribution
• Drug registration
• Specialty pharmaceuticals

Headquarters

HQ city

Ankeveen

HQ country

Netherlands

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

Core offering

Eurocept Pharmaceuticals develops, produces, registers, and markets medicinal products. The company serves healthcare providers and patients, operating an integrated pharmaceutical model that spans development through commercialization of drug products.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Broad incumbents

• Stada Arzneimittel: Stada is a large European-focused generics and specialty pharma company that develops, registers, and markets off-patent medicines across multiple EU markets. It is comparable to Eurocept because of its overlapping value chain (manufacture + registration + market) and emphasis on the same European regulatory regime, though at much greater scale.
• Zentiva: Zentiva is a pan-European generic pharmaceutical manufacturer and marketing-authorisation holder based in Prague with strong Benelux presence. Comparable to Eurocept as both companies operate the full develop–produce–register–market chain for off-patent medicines in Europe, though Zentiva operates at significantly greater scale.
• Almirall: Almirall is a Spanish-based European specialty pharmaceutical company focused on branded prescription medicines, dermatology, and CNS. Comparable to Eurocept because both are mid-sized European branded/specialty pharma companies developing, registering, and marketing medicines within EU regulatory frameworks, though Almirall is larger and listed.
• Sandoz (Novartis division): Sandoz is the global generics and biosimilars business of Novartis, one of the world's largest off-patent pharmaceutical manufacturers and registration holders. Comparable to Eurocept because both operate the manufacture–register–market model for off-patent medicines, though Sandoz operates globally and at far greater scale.

Direct peers

• Faes Farma: Faes Farma is a mid-sized Iberian pharmaceutical company that develops, manufactures, and markets prescription, OTC, and consumer-health medicines. It is a close peer to Eurocept because of similar scope (full pharma value chain), similar mid-market positioning, and similar Iberian/Benelux European geographic focus.
• Italfarmaco: Italfarmaco is a privately held mid-sized Italian pharmaceutical group that develops, manufactures, and markets proprietary and licensed medicines across Europe. It is directly comparable to Eurocept in size, value-chain coverage (develop/produce/register/market), and private European specialty-pharma profile.
• Polpharma: Polpharma is the largest Polish pharmaceutical manufacturer, producing APIs and finished dosage forms and marketing them across Europe. Comparable to Eurocept because both operate integrated pharmaceutical value chains within the EU regulatory system, with overlapping product focus on generics and OTC.

Emerging players

• Aspen Pharmacare: Aspen is a South African specialty pharmaceutical group that manufactures and markets branded and generic medicines internationally, including across Europe. It is comparable to Eurocept as a non-Western-rooted pharma expanding into European markets via the same develop/register/market model, though on a much larger scale.
• Glenmark Pharmaceuticals: Glenmark is an Indian-headquartered global pharmaceutical company with a strong European generics and specialty business. Comparable to Eurocept because both operate develop-and-market pharma models serving the EU market, although Glenmark has broader international scale and a more developed pipeline.

Others

• Eurofarma: Eurofarma is a large Brazilian pharmaceutical company that manufactures and markets medicines across Latin America with selective international expansion. It is thematically comparable to Eurocept as a vertically integrated emerging-market pharma but does not directly compete in the Benelux.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/eurocept

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eurocept Pharmaceuticals